NEJM January 1, 2025

Multidrug-resistant tuberculosis (MDR-TB) is a growing public health problem.1 Recently, the World Health Organization endorsed new regimens for the treatment of MDR-TB that rely on new and repurposed antibiotic agents (i.e., bedaquiline, pretomanid, and linezolid with or without moxifloxacin [BPaL/M]).2 Much of the global burden of MDR-TB is driven by patient-to-patient transmission of drug-resistant Mycobacterium tuberculosis3 and since BPaL/M is used to treat MDR-TB, resistance to these drugs that is emerging in patients with MDR-TB could spread. On the other hand, experimental...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Healthcare System, Pharma, Pharma / Biotech, Public Health / COVID
Related Articles:
The U.S. Government and the World Health Organization - 2
Moderna gets $590M from US government for bird flu vaccine
CDC: Flu activity remains high, COVID-19 increasing while RSV peaks
As H5N1 Is Detected In San Francisco, A Panel Discusses Next Steps
Donald Trump’s first steps on healthcare: Inaugural remarks, leaving the WHO, and more

Share This Article